RxDoctor Payments Data

Warren Buck, MD

Cardiovascular Disease · Edison, NJNPI 1720019532

Payments from drug & device makers

$3,509in general payments, 2019–2025

Across 251 payments — averaging $13.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$671
  • Novo Nordisk$618
  • Pfizer$432
  • Johnson & Johnson$272
  • Boehringer Ingelheim$260
  • GSK$218
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,509100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,509 in reported general payments places this provider in the 55th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$526,369
Medicare patients
276
Services billed
6,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban160$121,887
XareltoRivaroxaban57$39,970
JardianceEmpagliflozin35$25,020
MyrbetriqMirabegron41$22,272
OzempicSemaglutide14$21,562
OxycontinOxycodone Hcl13$16,935
Janumet XrSitagliptin Phos/Metformin Hcl19$10,528
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,768
LipitorAtorvastatin Calcium12$8,046
Icosapent Ethyl19$5,864
SynthroidLevothyroxine Sodium45$4,794
VesicareSolifenacin Succinate12$4,522
Dexlansoprazole DrDexlansoprazole14$4,011
Metoprolol Succinate229$3,714
Levothyroxine Sodium252$2,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Lipitor$432$129,933172 claims
Johnson & JohnsonXarelto$272$39,97057 claims
Boehringer IngelheimJardiance$260$25,02035 claims
Novo NordiskOzempic$618$21,56214 claims
MerckJanumet Xr$181$10,52819 claims
GSKTrelegy Ellipta$218$9,76815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Edison

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →